MiR-26a-5p Inhibits Cell Proliferation and Enhances Doxorubicin Sensitivity in HCC Cells via Targeting AURKA

被引:26
作者
Yuan, Yan Li [1 ]
Yu, HaiBo [2 ]
Mu, Sen-Mao [2 ]
Dong, Ya Dong [2 ]
Li, De Yu [2 ]
机构
[1] Zhengzhou Univ, Zhengzhou Childrens Hosp, Henan Childrens Hosp, Childrens Hosp, Zhengzhou, Henan, Peoples R China
[2] Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Hepatobiliary Pancreat Surg, Peoples Hosp, Zhengzhou, Henan, Peoples R China
关键词
MiR-26a-5p; hepatocellular carcinoma (HCC); aurora kinase A (AURKA); doxorubicin sensitivity; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; AURORA KINASE; PROSTATE-CANCER; MICRORNA; METASTASIS; MECHANISMS; RESISTANCE;
D O I
10.1177/1533033819851833
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To investigate the role of miR-26a-5p in cell proliferation and doxorubicin sensitivity in hepatocellular carcinoma. Methods: We evaluated miR-26a-5p expression in hepatocellular carcinoma tissues and cell lines by reverse transcription polymerase chain reaction. Cell Counting Kit-8 was used to examine cell proliferation. Relationship between miR-26a-5p and aurora kinase A was evaluated by luciferase report system. Western blot was used to detect expression of aurora kinase A. Results: In this study, we observed miR-26a-5p was downregulated in hepatocellular carcinoma tissues and cell lines. Gain-of-function experiments showed that proliferation rate of hepatocellular carcinoma cells decreased under condition of miR-26a-5p mimics. We found miR-26a-5p mimics could enhance doxorubicin sensitivity of hepatocellular carcinoma cells. Further study showed that aurora kinase A was target gene of miR-26a-5p. Suppression of aurora kinase A could lead to lower cell proliferation and higher doxorubicin sensitivity of hepatocellular carcinoma cells. Conclusion: Our study found that miR-26a-5p could inhibit cell proliferation and enhance doxorubicin sensitivity in hepatocellular carcinoma cells by targeting aurora kinase A.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 25 条
  • [1] Sorafenib Use in Hepatocellular Carcinoma: More Questions Than Answers
    Abou-Alfa, Ghassan K.
    [J]. HEPATOLOGY, 2014, 60 (01) : 15 - 18
  • [2] MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma
    Beckers, Anneleen
    Van Peer, Gert
    Carter, Daniel R.
    Gartlgruber, Moritz
    Herrmann, Carl
    Agarwal, Saurabh
    Helsmoortel, Hetty H.
    Althoff, Kristina
    Molenaar, Jan J.
    Cheung, Belamy B.
    Schulte, Johannes H.
    Benoit, Yves
    Shohet, Jason M.
    Westermann, Frank
    Marshall, Glenn M.
    Vandesompele, Jo
    De Preter, Katleen
    Speleman, Frank
    [J]. CANCER LETTERS, 2015, 366 (01) : 123 - 132
  • [3] miR-26a-5p suppresses tumor metastasis by regulating EMT and is associated with prognosis in HCC
    Chang, L.
    Li, K.
    Guo, T.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06) : 695 - 703
  • [4] AURKA promotes cancer metastasis by regulating epithelial-mesenchymal transition and cancer stem cell properties in hepatocellular carcinoma
    Chen, Chenlin
    Song, Guangyuan
    Xiang, Jue
    Zhang, Hongcheng
    Zhao, Shaoyun
    Zhan, Yinchu
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 486 (02) : 514 - 520
  • [5] Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations
    Chen, Xiaoli
    Lingala, Shilpa
    Khoobyari, Shiva
    Nolta, Jan
    Zern, Mark A.
    Wu, Jian
    [J]. JOURNAL OF HEPATOLOGY, 2011, 55 (04) : 838 - 845
  • [6] Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role
    Cochetti, Giovanni
    Poli, Giulia
    Guelfi, Gabriella
    Boni, Andrea
    Egidi, Maria Giulia
    Mearini, Ettore
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 7545 - 7553
  • [7] Causes and consequences of microRNA dysregulation in cancer
    Croce, Carlo M.
    [J]. NATURE REVIEWS GENETICS, 2009, 10 (10) : 704 - 714
  • [8] A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
    Dauch, Daniel
    Rudalska, Ramona
    Cossa, Giacomo
    Nault, Jean-Charles
    Kang, Tae-Won
    Wuestefeld, Torsten
    Hohmeyer, Anja
    Imbeaud, Sandrine
    Yevsa, Tetyana
    Hoenicke, Lisa
    Pantsar, Tatu
    Bozko, Przemyslaw
    Malek, Nisar P.
    Longerich, Thomas
    Laufer, Stefan
    Poso, Antti
    Zucman-Rossi, Jessica
    Eilers, Martin
    Zender, Lars
    [J]. NATURE MEDICINE, 2016, 22 (07) : 744 - 753
  • [9] Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition
    Finn, Richard S.
    [J]. LIVER CANCER, 2012, 1 (3-4) : 247 - 256
  • [10] Treatment of intermediate-stage hepatocellular carcinoma
    Fomer, Alejandro
    Gilabert, Marine
    Bruix, Jordi
    Raoul, Jean-Luc
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (09) : 525 - 535